Anti-Human CD196 (CCR6) FITC 25 tests
- Known as:
- Antibody toHuman CD196 (CCR6) fluorecein 25 tests
- Catalog number:
- 11-1969-41
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD196 (CCR6) FITC 25 tests
Related genes to: Anti-Human CD196 (CCR6) FITC 25 tests
- Gene:
- CCR6 NIH gene
- Name:
- C-C motif chemokine receptor 6
- Previous symbol:
- STRL22
- Synonyms:
- CKR-L3, GPR-CY4, CMKBR6, GPR29, DRY-6, DCR2, BN-1, CD196
- Chromosome:
- 6q27
- Locus Type:
- gene with protein product
- Date approved:
- 1997-04-21
- Date modifiied:
- 2016-03-14
Related products to: Anti-Human CD196 (CCR6) FITC 25 tests
Related articles to: Anti-Human CD196 (CCR6) FITC 25 tests
- Asthma is a heterogeneous chronic inflammatory syndrome, with the T2-high endotype defined by robust type 2 immune responses and skewed T helper polarization. Although H3K9 acetylation (H3K9ac) is a key activating histone mark in T helper differentiation, its genome-wide promoter landscape in circulating immune cells of T2-high asthma remains uncharacterized. - Source: PubMed
Publication date: 2026/09/16
González DanielInfante AlexLópez-Kleine LilianaCeschin DaniloFernández-Sánchez María JoséCañas-Arboleda AlejandraZafra-Mejía CarlosRojas Adriana - The present study aimed to assess the CCR6 and CD244 expression on natural killer (NK) and natural killer T (NKT) cells, considering their different subsets and examining their associations with molecular cytogenetics and clinical outcomes in newly diagnosed adult acute myeloid leukemia (AML) patients. - Source: PubMed
Publication date: 2026/08/31
Zahran Asmaa MRayan AmalRefaat AhmedElsayh Ahmad Khalid IbrahimHussein Nour Y HSabet Marwa ASeif Eldin SalwaFergany AyaNarouz Merna WMahboob Yomna RAlbadry M Zahran Zeinab - Triple-negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2-mediated downstream NF-κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor-associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2-NF-κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small-molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti-metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30-TNFR2-NF-κB-CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti-metastatic strategies in TNBC. - Source: PubMed
Publication date: 2026/09/09
Gao PingpingSun NaYang NingZhao TingtingFu RuiWu ZhenyuZhou YuqinTan XuanniZhang YiHan FeiQi Xiaowei - Few large-scale population-based studies have examined the association between COVID-19 and respiratory aspergillosis. Using nationwide data, we investigated whether SARS-CoV-2 infection increases respiratory aspergillosis incidence and whether COVID-19-associated aspergillosis affects COVID-19 severity. We also analyzed public COVID-19 transcriptomic datasets to assess effects on airway structural and immune cells. - Source: PubMed
Publication date: 2026/09/03
Kim Jong SeungPark Jun HyungKim JuhyunLee Yong ChulYang Ji WonYou Yeon SeokKim GwangsuKim WankyuJeong Jae Seok - The genus Aervacomprises diverse medicinal plant species traditionally used for various therapeutic purposes, yet their pharmacokinetic and toxicological profiles remain largely uncharacterized. This study aimed to evaluate a library of 125 phytochemicals derived from Aerva species using comprehensive in silico approaches. Drug-likeness, ADME parameters, and toxicity profiles were assessed using SwissADME and ProTox-II platforms. Six compounds (AJ26, AJ30, AJ39, AJ43, AJ47, AJ55) exhibited optimal pharmacokinetic properties, including high gastrointestinal absorption, favorable lipophilicity (log P: 1.54-2.56), and acceptable water solubility. All selected compounds met multiple drug-likeness criteria and showed no PAINS alerts. Toxicity analysis revealed low risk for hepatotoxicity, carcinogenicity, and immunotoxicity. Three GEO datasets (GSE22529, GSE26725 and GSE50006) were examined to investigate their therapeutic relevance in chronic lymphocytic leukemia (CLL). 164 common differentially expressed genes (DEGs) were identified, which were primarily associated with pathways of B-cell activation and immunity. The protein-protein interaction analysis identified the CD22, CD38, and CCR6 as strong hub genes, with CD22 had the highest diagnostic performance (average AUC = 0.939). Molecular docking showed that all the molecules showed good interactions with the corresponding receptors such as AJ26-CD38, AJ30-CD22 and AJ43-CCR6. These findings show that Aerva-derived compounds as interesting candidates for future preclinical development in phytochemical-based therapeutics. - Source: PubMed
Publication date: 2026/09/03
Afzal KinzaShafiq NusratRashid MaryamParveen Shagufta